144 related articles for article (PubMed ID: 19331137)
1. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Kolinsky K; Zhang YE; Dugan U; Heimbrook D; Packman K; Higgins B
Anticancer Res; 2009 Jan; 29(1):91-8. PubMed ID: 19331137
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.
Kolinsky K; Shen BQ; Zhang YE; Kohles J; Dugan U; Zioncheck TF; Heimbrook D; Packman K; Higgins B
Mol Cancer Ther; 2009 Jan; 8(1):75-82. PubMed ID: 19139115
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.
Higgins B; Kolinsky K; Linn M; Adames V; Zhang YE; Moisa C; Dugan U; Heimbrook D; Packman K
Anticancer Res; 2007; 27(4B):2279-87. PubMed ID: 17695515
[TBL] [Abstract][Full Text] [Related]
5. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
8. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
[No Abstract] [Full Text] [Related]
9. Common side effects and interactions of colorectal cancer therapeutic agents.
Holt K
J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
[No Abstract] [Full Text] [Related]
10. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
12. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine/irinotecan combination regimens in colorectal cancer.
Kerr DJ
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):27-9. PubMed ID: 12014865
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
15. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Cartwright T; McCollum D; Boehm KA
Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.
Ardavanis A; Kountourakis P; Mantzaris I; Malliou S; Doufexis D; Sykoutri D; Fragos I; Rigatos G
Anticancer Res; 2008; 28(5B):3087-92. PubMed ID: 19031962
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Rudek MA; Dasari A; Laheru D; He P; Jin R; Walker R; Taylor GE; Jimeno A; Donehower RC; Hidalgo M; Messersmith WA; Purcell WT
J Clin Pharmacol; 2016 Aug; 56(8):966-73. PubMed ID: 26632033
[TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Fuchs CS; Marshall J; Barrueco J
J Clin Oncol; 2008 Feb; 26(4):689-90. PubMed ID: 18235136
[No Abstract] [Full Text] [Related]
19. [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Kocáková I; Kocák I; Svoboda M; Nemecek R; Rehák Z; Standara M
Klin Onkol; 2009; 22(2):73-6. PubMed ID: 19522377
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]